SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PROGRAM

监测、流行病学和最终结果（SEER）计划是由美国国家癌症研究所（NCI）建立的，旨在定期收集和报告基于人群的癌症发病率和生存率数据。它是NCI监测活动的核心组成部分，为规划癌症控制和研究计划提供信息，并评估这些计划对癌症发病率的影响。 SEER计划于1972年启动，以响应国家癌症计划的要求，评估美国癌症负担的程度，并确定与癌症风险和/或患者生存相关的因素。SEER模式护理研究描述，表征和比较美国不同地理区域的癌症实践模式和治疗方法。进行SEER护理模式研究是为了满足国会指令（根据公法100-607，第100节）。413（a）（2）（C）通过1988年11月4日），以国家癌症研究所评估纳入最先进的癌症治疗的临床实践和癌症患者接受此类治疗的程度，并将此类评估的结果纳入两年期报告中。为了选择符合这一指令的癌症，癌症控制和人口科学司一直与癌症治疗司密切合作。今年的护理模式（POC）研究将调查2010年诊断的早期乳腺癌、II期和III期结直肠癌、非小细胞肺癌的最先进疗法。

The Surveillance, Epidemiology, and End Results (SEER) Program was established by the National Cancer Institute (NCI) to collect and report periodically on population-based cancer incidence and survival data. It is a core component of the NCI's surveillance activities which provide information used for planning cancer control and research programs, and for evaluating the impact of such programs on cancer rates. The SEER Program was initiated in 1972 in response to requirements of the National Cancer Program for assessing the magnitude of the cancer burden in the United States, and for identifying factors related to cancer risk and/or patient survival. SEER Patterns of Care Studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. SEER Patterns of Care Studies are conducted to satisfy a Congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted November 4, 1988) to the National Cancer Institute to ¿assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports¿¿. To select the cancers to satisfy this directive, the Division of Cancer Control and Population Sciences has been working closely with the Division of Cancer Treatment. This year's Pattern's of Care (POC) Study will investigate state-of-the-art therapies for early stage breast, Stage II and III colorectal, non-small cell lung cancer diagnosed in 2010.